These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

605 related articles for article (PubMed ID: 34426012)

  • 1. Prevalence of Chronic Kidney Disease in Type 2 Diabetes: The Canadian REgistry of Chronic Kidney Disease in Diabetes Outcomes (CREDO) Study.
    Chu L; Fuller M; Jervis K; Ciaccia A; Abitbol A
    Clin Ther; 2021 Sep; 43(9):1558-1573. PubMed ID: 34426012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High unmet treatment needs in patients with chronic kidney disease and type 2 diabetes: real-world evidence from a US claims database.
    Fried L; Schmedt N; Folkerts K; Bowrin K; Raad H; Batech M; Kovesdy C
    Nephrol Dial Transplant; 2023 Feb; 38(3):630-643. PubMed ID: 35389468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY
    Prázný M; Suplotova L; Gumprecht J; Kamenov Z; Fülöp T; Medvedchikov A; Rosenzweig D; Aleksandric M
    Cardiovasc Diabetol; 2022 Oct; 21(1):203. PubMed ID: 36209118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concordance With Screening and Treatment Guidelines for Chronic Kidney Disease in Type 2 Diabetes.
    Edmonston D; Lydon E; Mulder H; Chiswell K; Lampron Z; Marsolo K; Goss A; Ayoub I; Shah RC; Chang AR; Ford DE; Jones WS; Fonesca V; Machineni S; Fort D; Butler J; Hunt KJ; Pitlosh M; Rao A; Ahmad FS; Gordon HS; Hung AM; Hwang W; Bosworth HB; Pagidipati NJ
    JAMA Netw Open; 2024 Jun; 7(6):e2418808. PubMed ID: 38922613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient characteristics and initiation of mineralocorticoid receptor antagonists in patients with chronic kidney disease in routine clinical practice in the US: a retrospective cohort study.
    Blankenburg M; Fett AK; Eisenring S; Haas G; Gay A
    BMC Nephrol; 2019 May; 20(1):171. PubMed ID: 31096928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ACE inhibitor or ARB treatment among patients with diabetes and chronic kidney disease.
    Fried LF; Petruski-Ivleva N; Folkerts K; Schmedt N; Velentgas P; Kovesdy CP
    Am J Manag Care; 2021 Dec; 27(20 Suppl):S360-S368. PubMed ID: 34878753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of cardiorenal outcomes and incidence of genitourinary tract infection after combined SGLT2 inhibitor and ACEI/ARB use in patients with chronic kidney disease stages 3-5: A real-world retrospective cohort study in Taiwan.
    Shao YJ; Chen WT; Yu SM; Tsou LL; Hsu YH; Wu MS; Kao YH; Chou CL; Hsiao PJ
    Int J Med Sci; 2024; 21(11):2109-2118. PubMed ID: 39239537
    [No Abstract]   [Full Text] [Related]  

  • 8. Contemporary use of cardiovascular risk reduction strategies in type 2 diabetes. Insights from the diabetes collaborative registry.
    Arnold SV; Gosch K; Kosiborod M; Wong ND; Sperling LS; Newman JD; Gamble CL; Hamersky C; Rajpura J; Vaduganathan M
    Am Heart J; 2023 Sep; 263():104-111. PubMed ID: 37164146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus.
    Lv R; Xu L; Che L; Liu S; Wang Y; Dong B
    Front Endocrinol (Lausanne); 2023; 14():1125693. PubMed ID: 36860374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-steroidal mineralocorticoid antagonists and hyperkalemia monitoring in chronic kidney disease patients associated with type II diabetes: a narrative review.
    Morales J; Palmer BF
    Postgrad Med; 2024 Mar; 136(2):111-119. PubMed ID: 38344772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient and disease characteristics of type-2 diabetes patients with or without chronic kidney disease: an analysis of the German DPV and DIVE databases.
    Bramlage P; Lanzinger S; van Mark G; Hess E; Fahrner S; Heyer CHJ; Friebe M; Seufert J; Danne T; Holl RW
    Cardiovasc Diabetol; 2019 Mar; 18(1):33. PubMed ID: 30878037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus.
    Wish JB; Pergola P
    Mayo Clin Proc Innov Qual Outcomes; 2022 Dec; 6(6):536-551. PubMed ID: 36277502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade.
    Shenoy SV; Nagaraju SP; Bhojaraja MV; Prabhu RA; Rangaswamy D; Rao IR
    Nephrology (Carlton); 2021 Nov; 26(11):858-871. PubMed ID: 34176194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescription of guideline-directed medical therapies in patients with diabetes and chronic kidney disease from the CURE-CKD Registry, 2019-2020.
    Nicholas SB; Daratha KB; Alicic RZ; Jones CR; Kornowske LM; Neumiller JJ; Fatoba ST; Kong SX; Singh R; Norris KC; Tuttle KR
    Diabetes Obes Metab; 2023 Oct; 25(10):2970-2979. PubMed ID: 37395334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of chronic kidney disease in type 2 diabetes: screening, diagnosis and treatment goals, and recommendations.
    Shubrook JH; Neumiller JJ; Wright E
    Postgrad Med; 2022 May; 134(4):376-387. PubMed ID: 34817311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An analysis of DPV and DIVE registry patients with chronic kidney disease according to the finerenone phase III clinical trial selection criteria.
    Bramlage P; Lanzinger S; Mühldorfer S; Milek K; Gillessen A; Veith R; Ohde T; Danne T; Holl RW; Seufert J
    Cardiovasc Diabetol; 2023 May; 22(1):108. PubMed ID: 37158855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?
    Silvariño R; Rios P; Baldovinos G; Chichet MA; Perg N; Sola L; Saona G; De Souza N; Lamadrid V; Gadola L
    Nephron; 2019; 143(2):100-107. PubMed ID: 31203280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade of Renin-Angiotensin-Aldosterone System in Elderly Patients with Heart Failure and Chronic Kidney Disease: Results of a Single-Center, Observational Cohort Study.
    Martínez-Milla J; García MC; Urquía MT; Castillo ML; Arbiol AD; Monteagudo ALR; Mariscal MLM; Figuero SB; Franco-Pelaéz JA; Tuñón J
    Drugs Aging; 2019 Dec; 36(12):1123-1131. PubMed ID: 31493202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape.
    Mende CW
    Adv Ther; 2022 Jan; 39(1):148-164. PubMed ID: 34846711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimated Lifetime Benefit of Combined RAAS and SGLT2 Inhibitor Therapy in Patients with Albuminuric CKD without Diabetes.
    Vart P; Vaduganathan M; Jongs N; Remuzzi G; Wheeler DC; Hou FF; McCausland F; Chertow GM; Heerspink HJL
    Clin J Am Soc Nephrol; 2022 Dec; 17(12):1754-1762. PubMed ID: 36414316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.